Evidence map›Paper›PMID 39834908›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2025

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy.

Hironori Ochi, Masayuki Kurosaki, Takaaki Tanaka, Nobuharu Tamaki, Kaoru Tsuchiya, Yutaka Yasui, Hiroyuki Marusawa, Toshifumi Tada, Shinichiro Nakamura, Takehiro Akahane and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hironori OchiCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital Ehime Japan.ORCID https://orcid.org/0009-0002-1961-0899
Masayuki KurosakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Takaaki TanakaCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital Ehime Japan.
Nobuharu TamakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Kaoru TsuchiyaDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Yutaka YasuiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Hiroyuki MarusawaDepartment of Gastroenterology and Hepatology Osaka Red Cross Hospital Osaka Japan.
Toshifumi TadaDepartment of Internal Medicine Himeji Red Cross Hospital Hyogo Japan.ORCID https://orcid.org/0000-0002-0976-6761
Shinichiro NakamuraDepartment of Internal Medicine Himeji Red Cross Hospital Hyogo Japan.
Takehiro AkahaneDepartment of Gastroenterology Ishinomaki Red Cross Hospital Miyagi Japan.
Eisuke OkamotoDepartment of Gastroenterology Masuda Red Cross Hospital Shimane Japan.
Haruhiko KobashiDepartment of Gastroenterology Japanese Red Cross Okayama Hospital Okayama Japan.
Hirotaka AraiDepartment of Gastroenterology Maebashi Red Cross Hospital Gunma Japan.
Michiko NonogiDepartment of Gastroenterology Tokushima Red Cross Hospital Tokushima Japan.ORCID https://orcid.org/0000-0002-8337-4846
Namiki IzumiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: We investigated the impact of proteinuria on the therapeutic effect before lenvatinib administration as second-line treatment after atezolizumab-bevacizumab. Methods: We examined 64 patients who were administered lenvatinib as second-line treatment after discontinuation of atezolizumab and bevacizumab. Proteinuria assessed before lenvatinib administration was considered severe if the qualitative value test (QV) was 3+ or the urine protein/creatinine ratio (UPCR) was ≥ 2.0 (group A, Results: In the entire cohort, the modified albumin-bilirubin grades were grades 1, 2a, 2b, and 3 in 12, 21, 26, and 5 patients, respectively. Regarding the Barcelona Clinic of Liver Cancer stage, 2, 22, and 40 patients had stages A, B, and C, respectively. The objective response rate (ORR) was 14.0% and the disease control rate (DCR) was 59.3%. The median survival time and progression free survival after administration of lenvatinib was 14.8 (95% confidence interval [CI], 11.3-18.4) and 5.5 (95% CI, 3.6-7.5) months, respectively. The ORR and DCR were 0% and 38.4% for group A ( Conclusions: Severe proteinuria before lenvatinib as a second-line therapy after atezolizumab-bevacizumab treatment may affect the duration of lenvatinib administration and treatment efficacy.

Indexed as

atezolizumab‐bevacizumabhepatocellular carcinomalenvatinibproteinuria

Identifiers

PMID39834908
PMCPMC11743979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.